| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.9 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |